Bibliographic Details
| Title: |
Immunostimulatory Nucleic Acid Packaged Particles for the Treatment of Hypersensitivity |
| Document Number: |
20100303846 |
| Publication Date: |
December 2, 2010 |
| Appl. No: |
12/576086 |
| Application Filed: |
October 08, 2009 |
| Abstract: |
The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy. |
| Inventors: |
RENNER, Wolfgang A. (Kilchberg, CH); BACHMANN, Martin F. (Seuzach, CH); CIELENS, Indulis (Riga, LV); COESTER, Conrad Johannes (Neuhof, DE); DIETMEIER, Klaus (Zurich, CH); FUCHS, Sebastian (Munchen, DE); MANOLOVA, Vania (Zurich, CH); MAURER, Patrik (Winterthur, CH); PUMPENS, Paul (Riga, LV); RENHOFA, Regina (Riga, LV); TISSOT, Alain (Zurich, CH); ZOU, Yu (Birmensdorf, CH) |
| Assignees: |
Cytos Biotechnology AG (Zurich-Schlieren, CH) |
| Claim: |
1. A method of treating hypersensitivity in an animal, wherein said hypersensitivity is allergy, asthma, or dermatitis, wherein said method comprises introducing a composition into said animal, and wherein said composition comprises, essentially consists of, or consists of: (a) a virus-like particle, wherein said virus-like particle is a virus-like particle of an RNA bacteriophage; and (b) an immunostimulatory nucleic acid, wherein said immunostimulatory nucleic acid is an unmethylated CpG-containing oligonucleotide; wherein said particle is packaged with said immunostimulatory nucleic acid, and wherein said composition is free of an allergen or an allergen extract. |
| Claim: |
2-6. (canceled) |
| Claim: |
7. The method of claim 1, wherein said virus-like particle comprises, or alternatively essentially consists of, alternatively consists of coat proteins, or fragments thereof, of a RNA bacteriophage. |
| Claim: |
8. (canceled) |
| Claim: |
9. The method of claim 1, wherein said RNA bacteriophage is Qβ. |
| Claim: |
10. The method of claim 1, wherein said RNA bacteriophage is AP205. |
| Claim: |
11-25. (canceled) |
| Claim: |
26. The method of claim 1, wherein the CpG motif of said unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, wherein said palindromic sequence is GACGATCGTC (SEQ ID NO:28), and wherein said palindromic sequence is flanked at its 5′-terminus by at least 3 and at most 15 guanosine entities, and wherein said palindromic sequence is flanked at its 3′-terminus by at least 3 and at most 15 guanosine entities. |
| Claim: |
27-30. (canceled) |
| Claim: |
31. The method of claim 1, wherein said unmethylated CpG-containing oligonucleotide comprises, or alternatively consists essentially of, or alternatively consists of the sequence GGGGGGGGGG GACGATCGTC GGGGGGGGGG (SEQ ID NO:27). |
| Claim: |
32. The method of claim 1, wherein said unmethylated CpG-containing oligonucleotide consists exclusively of phosphodiester bound nucleotides. |
| Claim: |
33-39. (canceled) |
| Claim: |
40. The method of claim 1, wherein said hypersensitivity is asthma. |
| Claim: |
41. The method of claim 40, wherein said asthma is IgE-mediated asthma. |
| Claim: |
42. The method of claim 1, wherein said hypersensitivity is dermatitis. |
| Claim: |
43. The method of claim 42, wherein said dermatitis is an atopic eczema. |
| Claim: |
44. The method of claim 1, wherein said hypersensitivity is an IgE-mediated allergy (type I allergy). |
| Claim: |
45. (canceled) |
| Claim: |
46. (canceled) |
| Claim: |
47. The method of claim 1, wherein said IgE-mediated allergy is pollen allergy or house dust allergy. |
| Claim: |
48-53. (canceled) |
| Claim: |
54. The method of claim 1, wherein said animal is a human. |
| Claim: |
55. (canceled) |
| Claim: |
56. (canceled) |
| Claim: |
57. The method of claim 1, wherein said composition is introduced in said animal without an allergen or allergen extract. |
| Claim: |
58. The method of claim 1, wherein said composition is introduced in said animal without administration of an allergen or allergen extract. |
| Claim: |
59. The method of claim 1, wherein said composition is introduced in said animal not in conjunction with an allergen or allergen extract. |
| Claim: |
60. (canceled) |
| Claim: |
61. (canceled) |
| Claim: |
62. The method of claim 1, wherein said composition is introduced in said animal, and wherein said introduction of said composition into said animal is effected such as an allergen or allergen extract is not introduced in said animal for at least eight weeks before and at least eights weeks after said introduction of said composition in said animal. |
| Claim: |
63. The method of claim 1, wherein said composition is introduced in said animal, and wherein said introduction of said composition into said animal is effected such as an allergen or allergen extract is not introduced at all in said animal. |
| Claim: |
64-79. (canceled) |
| Claim: |
80. The method of claim 9, wherein said virus-like particle essentially consists of coat proteins having the amino acid sequence of SEQ ID NO:3. |
| Current U.S. Class: |
4241/861 |
| Current International Class: |
61; 61; 61 |
| Accession Number: |
edspap.20100303846 |
| Database: |
USPTO Patent Applications |
